Evenity (Romosozumab) Pediatric Safety: What Clinicians and Parents Need to Know About Use Under Age 12

Why Romosozumab Has No Pediatric Approval

Romosozumab received FDA approval in April 2019 exclusively for postmenopausal women with osteoporosis at high risk for fracture [2]. The approval was based on adult trials including FRAME and ARCH, which enrolled postmenopausal women aged 55 to 90. No pediatric population was included in any key study.

The Regulatory Gap

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in pediatric populations unless granted a waiver. Amgen received a waiver for romosozumab because the adult indication (postmenopausal osteoporosis) does not occur in children [3]. This waiver means the manufacturer has no regulatory obligation to conduct pediatric trials, and none are currently underway or registered on ClinicalTrials.gov.

What the Label States

The Evenity prescribing information explicitly states: "Safety and effectiveness in pediatric patients have not been established" [2]. This is not a provisional statement pending data. It reflects a complete absence of pediatric pharmacokinetic, pharmacodynamic, and safety information for this drug.

How Sclerostin Inhibition Could Affect Growing Bone

Understanding why romosozumab raises unique pediatric concerns requires a brief look at what sclerostin does in the developing skeleton. In adults, sclerostin acts as a brake on bone formation by inhibiting the Wnt signaling pathway in osteocytes [4]. Blocking sclerostin releases that brake, allowing rapid new bone formation. That is the therapeutic rationale in osteoporosis.

Sclerostin in the Growth Plate

In children, the picture is different. Sclerostin is expressed not only in mature osteocytes but also in hypertrophic chondrocytes within the growth plate [5]. The growth plate is the engine of longitudinal bone growth, and its regulation depends on tightly coordinated signaling between Wnt, Indian hedgehog, and parathyroid hormone-related peptide pathways. Blocking sclerostin in this environment could, in theory, accelerate premature growth plate closure, disrupt chondrocyte maturation, or produce abnormal bone architecture.

Lessons from Sclerosteosis and Van Buchem Disease

Genetic loss-of-function mutations in the SOST gene (which encodes sclerostin) cause sclerosteosis and van Buchem disease. These conditions produce dense, overgrown bone from childhood onward, with complications including cranial nerve compression, elevated intracranial pressure, and syndactyly [6]. While romosozumab does not eliminate sclerostin entirely, these genetic conditions illustrate what happens when sclerostin signaling is chronically reduced during skeletal development. A 12-month course of romosozumab in a child would create a pharmacologic version of partial sclerostin deficiency during a period of active bone modeling.

Preclinical Animal Data and Its Limits

No juvenile animal toxicology studies for romosozumab have been published. The preclinical program used adult rats and cynomolgus monkeys [7]. In adult rats, romosozumab-analog treatment increased bone mineral density at cortical and trabecular sites. In adult monkeys, the anti-sclerostin antibody produced dose-dependent increases in bone formation markers without observed toxicity over study durations of up to 6 months.

Why Adult Animal Data Cannot Be Extrapolated to Pediatric Use

These results are encouraging for the adult indication but say nothing about effects on open growth plates, actively modeling metaphyses, or the developing cranial vault. Juvenile animal studies are the standard preclinical requirement before pediatric clinical trials can begin [8]. Without them, there is no preclinical safety foundation for pediatric dosing.

The absence of juvenile animal data also means there are no dose-response curves for skeletal toxicity in growing animals. Weight-based dosing, which is routine for most pediatric biologics, cannot be estimated for romosozumab because the therapeutic index in immature bone is unknown.

The Cardiovascular Boxed Warning and Pediatric Implications

Romosozumab carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death [2]. In the ARCH trial (N=4,093), major adverse cardiovascular events occurred in 2.5% of romosozumab-treated patients versus 1.9% of alendronate-treated patients over 12 months [1].

Cardiovascular Risk in Children

Atherosclerotic cardiovascular events are rare in children. However, the mechanism by which romosozumab may increase cardiovascular risk is not fully understood. Proposed mechanisms include effects on vascular calcification through Wnt pathway modulation in vascular smooth muscle cells [9]. Children with chronic diseases that require consideration of bone-active agents (such as osteogenesis imperfecta, cerebral palsy, or glucocorticoid-induced osteoporosis) often have comorbidities affecting the vasculature. Introducing a drug with an unexplained cardiovascular signal into this population, without specific safety data, would be difficult to justify.

What Clinicians Should Consider

For any off-label pediatric use discussion, the cardiovascular boxed warning should be weighed alongside the complete absence of pediatric efficacy data. A drug with an uncharacterized cardiovascular mechanism and zero pediatric trials represents a risk-benefit equation that cannot be calculated, only assumed.

Pediatric Osteoporosis: What Treatments Actually Have Safety Data

Pediatric osteoporosis is a real clinical entity. Children with osteogenesis imperfecta, glucocorticoid-dependent conditions, immobility-related bone loss, or cancer treatment-induced osteoporosis can develop painful vertebral compression fractures. Effective treatments exist, and several have decades of pediatric safety data.

Intravenous Bisphosphonates

IV pamidronate is the most extensively studied bone-active drug in pediatric populations. In osteogenesis imperfecta, cyclical IV pamidronate (administered every 2 to 4 months) has been used since the 1990s. A landmark study by Glorieux et al. (N=30, ages 3 to 16) demonstrated a 1.9% per year increase in lumbar spine areal BMD with significant reduction in fracture incidence over 1.5 years of treatment [10]. Long-term follow-up studies extending beyond 4 years have confirmed sustained benefits without growth plate fusion or impaired longitudinal growth.

Zoledronic Acid

IV zoledronic acid has pediatric data in osteogenesis imperfecta. A randomized trial by Baroncelli et al. Compared zoledronic acid to pamidronate in children and found comparable efficacy with a more convenient dosing schedule (every 6 months versus every 2 to 4 months) [11]. The safety profile included transient acute-phase reactions (fever, myalgia) but no growth disturbances.

Oral Bisphosphonates

Oral alendronate has been studied in children with osteogenesis imperfecta in a randomized, placebo-controlled trial (N=139, ages 4 to 19), showing significant BMD increases over 2 years with a safety profile similar to placebo [12]. While oral bisphosphonate adherence can be challenging in children, the safety data exists to support its use when IV access is a barrier.

Denosumab in Pediatric Populations

Denosumab (Prolia/Xgeva), another anti-resorptive biologic, has limited but growing pediatric data, primarily in giant cell tumor of bone and osteogenesis imperfecta case series [13]. Its mechanism (RANKL inhibition) is distinct from sclerostin inhibition, and the rebound vertebral fracture risk after discontinuation is a documented concern that requires careful management in all age groups [14].

Off-Label Use: Ethical and Legal Considerations

Off-label prescribing is common in pediatrics. An estimated 50% to 75% of medications used in children are prescribed off-label due to the historical exclusion of children from clinical trials [15]. However, off-label use is expected to be supported by some level of evidence, even if that evidence falls short of a randomized controlled trial.

The Evidence Threshold for Romosozumab Off-Label Pediatric Use

For romosozumab, the evidence threshold is not partially met. It is entirely absent. There are no case reports, no case series, no pharmacokinetic studies, no retrospective analyses, and no juvenile animal data. The theoretical risk profile (growth plate disruption, cranial overgrowth, unknown cardiovascular effects in children) is supported by biological plausibility from genetic loss-of-function conditions.

Institutional Review and Liability

Any clinician considering off-label romosozumab in a child would face significant informed consent challenges. The inability to provide patients or parents with any data on expected benefits, dose selection, monitoring parameters, or adverse event probability makes standard informed consent nearly impossible to construct. Institutional pharmacy and therapeutics committees would likely require a formal investigational protocol rather than a simple off-label prescription.

Monitoring Considerations If Exposure Occurs

In rare scenarios where a child might be inadvertently exposed to romosozumab (medication error, accidental injection), clinicians should understand what to monitor.

Immediate Assessment

A single 210 mg dose of romosozumab in a child would deliver a substantially higher mg/kg dose than intended in adults. The pharmacokinetics in children are unknown, but based on adult data, peak serum concentrations occur approximately 5 days after subcutaneous injection, with a half-life of approximately 12.8 days [2]. This means that any effects of a single accidental dose would persist for weeks.

Recommended Monitoring After Accidental Exposure

Serum calcium and phosphorus should be checked at baseline and at 7 and 14 days post-exposure, as the rapid increase in bone formation could theoretically produce hypocalcemia, similar to the "hungry bone" phenomenon seen after parathyroidectomy. Bone turnover markers (P1NP, CTX) could document the pharmacodynamic effect but would not change acute management. Growth velocity should be tracked at standard intervals for at least 12 months after exposure.

When to Involve Subspecialty Care

A pediatric endocrinologist should be consulted for any confirmed romosozumab exposure in a child under 12. If the child has a pre-existing bone disorder, the treating metabolic bone specialist should also be notified. Reporting the exposure to the FDA's MedWatch system is appropriate regardless of whether adverse effects are observed.

Future Research Directions

Could Romosozumab Ever Have a Pediatric Role?

The theoretical appeal exists. Sclerostin inhibition produces anabolic bone effects (new bone formation) rather than purely anti-resorptive effects (slowing bone loss). For conditions like severe osteogenesis imperfecta, where bone quality is fundamentally impaired, an anabolic agent could offer benefits that bisphosphonates cannot. Teriparatide, the only other approved anabolic bone agent, carries a contraindication in patients with open epiphyses due to the osteosarcoma signal in juvenile rats [16].

What Would Be Required

A responsible development pathway for pediatric romosozumab would need to include juvenile rat and primate toxicology studies with growth plate histomorphometry, single-ascending-dose pharmacokinetic studies in adolescents (likely ages 12 to 17 first), formal growth monitoring protocols extending years beyond treatment, and cardiovascular safety adjudication designed for a low-event-rate population. None of these steps are currently planned by Amgen or UCB.

The Setrusumab Precedent

Setrusumab, another anti-sclerostin antibody developed by Mereo BioPharma (later acquired by Ultragenyx), has been studied in osteogenesis imperfecta in adults and adolescents. The ASTEROID study (NCT05125705) enrolled patients aged 5 and older with type I, III, or IV OI [17]. If setrusumab generates pediatric safety and efficacy data, it could indirectly inform the biological plausibility of sclerostin inhibition in young patients, although direct extrapolation to romosozumab would remain inappropriate given different antibody characteristics and dosing.

The Bottom Line for Clinicians

Romosozumab has zero pediatric safety data: no trials, no case series, no juvenile animal studies, no pharmacokinetic modeling in children. The biological rationale for concern is strong, grounded in the known role of sclerostin in growth plate physiology and the clinical phenotype of genetic sclerostin deficiency. Combined with an unexplained cardiovascular boxed warning, the risk-benefit profile in children under 12 is uncharacterizable.

For pediatric patients who need bone-active therapy, IV pamidronate remains the most evidence-supported option, with oral alendronate and IV zoledronic acid as alternatives. Referral to a pediatric metabolic bone disease specialist is appropriate for any child with recurrent fragility fractures or densitometric osteoporosis (BMD Z-score ≤ -2.0 adjusted for age, sex, and body size per the 2019 ISCD Pediatric Official Positions).